Latest / CareTalk: Healthcare. Unfiltered. / Clincierge's Keys to Clinical Trial Success w/ CEO, Scott Gray | HealthBiz Brief
Transcript
- 0:00[Music] welcome to health Biz briefs with me David Williams from Health business group I'm here today with Scott Gray CEO of Clint searge Scott great to have you with me a pleasure to be with you David let's talk about retention in clinical trials we talk about recruitment sometimes say retention but retention specifically is that a big deal for clinical trials retention is a big deal for clinical trials because it's a big headache for clinical trials typical Dropout rates have been 30 to 40% average across clinical trials um with cliner services with among the patients that we support our retention rates are better than 90% so there's a significant increase in the speed of the timeline that companies can get where they can get their outcomes data and then come to Market faster to begin recovering there their R&D investment faster so it's a it's a key aspect in the performance of Trials and why is it that somebody would drop out I mean what are the what are the main reasons for that or is it just all over the place so there are many different aspects we we actually did a study uh a year and a half ago called our voice of the patient study where we asked some of those specific questions and we see um uh responses such as the inability to continue purchasing airline tickets for the travel that's required for this particular study visits and wait for the reimbursement they had to choose between mortgage or travel and they had to choose mortgage something like that um other aspects would be um the anxiety of having to organize the trip and what happens if there's a cancellation along the way and you've got a child and a wheelchair not only do you have to navigate what that aspect of your life life is now you have to figure out the logistics and and rebooking everything and again and again people um it's just another layer of complexity beyond what has to happen medically that if we remove that we're able to increase the retention in the in the trial so I love the the the name cliners because it pretty makes it pretty obvious that you're doing a you know concierge for for clinical care how did you have that that concept and how did you decide to apply it in the clinical trial space well my my background in corporate meetings and events so often went to nice hotels where there was a concierge in the lobby who would help you with your Logistics locally you know going out to dinner or going to see an event or something like that and in in the the U with the the thoughts in mind that we were going to create that type of Serv service but in the clinical space that's how I ended up mashing up those two words clinical and concierge great and I assume it's been received pretty well it has been yeah even even though we we did a a uh a marketing project the beginning of 2016 to try to come up with a better name yeah and we went through we went through all the Greek and Roman gods and all of that we still landed back where we started with clinty a that sounds that sounds good now I want to ask about I thinker related topic which is about diversity uh equity and inclusion in clinical trials I can imagine this is also usually framed in terms of recruitments so I'm wondering whether Recruitment and then also retention uh of a you know a broader more diverse set of clinical trial participants if that's related you know if you address that uh as well in your work it is what what sponsors are finding is that with the availability of our services where which are funded by the R&D budget so we're able to purchase air travel ground transport Etc to support the patients they now have access to those patients who previously didn't have the financial ability to purchase those things on their own so that a uh so that they or perhaps a child within the family could could participate so our services are showing that we can level the socioeconomic playing field of people who are enrolled in trials and help them meet some of the newer guidelines that are coming out even with the FDA where the expectation is that a broader spectrum of people with differing genetic makeup are are enrolled in the trial so that the outcomes data are broader great well Scott Gray CEO of Clint sege thanks for joining me today on health Biz briefs a pleasure to be with you David[Music]